Supramolecular control over the variability of color and fluorescence in low-molecular-weight glass

被引:0
|
作者
Zhang, Yunfei [1 ]
Cai, Changyong [1 ]
Li, Fenfang [2 ]
Tan, Xin [3 ]
Li, Qing [4 ]
Ni, Xinlong [5 ]
Dong, Shengyi [1 ]
机构
[1] Hunan Univ, Coll Chem & Chem Engn, Changsha 410082, Peoples R China
[2] Cent South Univ, Coll Chem & Chem Engn, Changsha 410083, Peoples R China
[3] Hunan Univ Technol, Coll Life Sci & Chem, Zhuzhou 412000, Peoples R China
[4] Guizhou Univ, Coll Chem & Chem Engn, Guiyang 50025, Peoples R China
[5] Hunan Normal Univ, Coll Chem & Chem Engn, Changsha 410081, Peoples R China
基金
中国国家自然科学基金;
关键词
BEHAVIOR; LIQUIDS; DNA;
D O I
10.1039/d4mh00609g
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Colorful and fluorescent transparent materials have been extensively used in industrial and scientific activities, with inorganic and polymeric glasses being the most typical representatives. Recently, artificial glass originating from low-molecular-weight monomers has attracted considerable attention. Compared with the deep understanding of the building blocks and driving forces of supramolecular glass, related studies on its optical properties are insufficient in terms of systematicness and pertinence. In this study, a supramolecular strategy was applied to introduce versatile colors and fluorescence emissions into a low-molecular-weight glass. Pillar[5]arene and cucurbit[8]uril were selected to recognize the functional components and yield the desired optical performances. Macrocycle-based host-guest chemistry endows artificial glass with controllable and programmable colors and fluorescence emissions. The color and fluorescence of supramolecular glass were controlled by the non-covalent approach.
引用
收藏
页码:5641 / 5649
页数:9
相关论文
共 50 条
  • [41] LOW-MOLECULAR-WEIGHT HEPARIN(S)
    BARROWCLIFFE, TW
    BRITISH JOURNAL OF HAEMATOLOGY, 1995, 90 (01) : 1 - 7
  • [42] PHARMACOKINETICS OF LOW-MOLECULAR-WEIGHT HEPARINS
    BARA, L
    SAMAMA, M
    ACTA CHIRURGICA SCANDINAVICA, 1990, : 57 - 61
  • [43] Low-molecular-weight heparin and outcomes
    Arbit, E
    CHEST, 2005, 128 (01) : 471 - 471
  • [44] HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARINS
    HIRSH, J
    CORONARY ARTERY DISEASE, 1992, 3 (11) : 990 - 1002
  • [45] PHARMACOLOGY OF LOW-MOLECULAR-WEIGHT HYDROXYETHYLSTARCHES
    BARON, JF
    ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION, 1992, 11 (05): : 509 - 515
  • [46] LOW-MOLECULAR-WEIGHT RHEUMATOID FACTOR
    CHODIRKER, WB
    TOMASI, TB
    JOURNAL OF CLINICAL INVESTIGATION, 1963, 42 (06): : 876 - &
  • [47] LOW-MOLECULAR-WEIGHT HEPARIN TO BE MARKETED
    不详
    CLINICAL PHARMACY, 1993, 12 (07): : 471 - &
  • [48] Low-molecular-weight heparin and cancer
    Zacharski, LR
    Ornstein, DL
    Mamourian, AC
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2000, 26 : 69 - 77
  • [49] Low-molecular-weight heparin and thrombocytopenia
    Silver, D
    VASCULAR SURGERY, 1997, 31 (04): : 409 - 411
  • [50] Low-molecular-weight heparins and thrombocytosis
    Liautard, C
    Nunes, AMC
    Vial, T
    Chatillon, F
    Guy, C
    Ollagnier, M
    Descotes, J
    ANNALS OF PHARMACOTHERAPY, 2002, 36 (09) : 1351 - 1354